IDEAS home Printed from https://ideas.repec.org/f/phi233.html
   My authors  Follow this author

Sebastian Hinde

Personal Details

First Name:Sebastian
Middle Name:
Last Name:Hinde
Suffix:
RePEc Short-ID:phi233

Affiliation

Centre for Health Economics
Department of Economics and Related Studies
University of York

York, United Kingdom
https://www.york.ac.uk/che/
RePEc:edi:chyoruk (more details at EDIRC)

Research output

as
Jump to: Working papers Articles

Working papers

  1. Karl Claxton & Steve Martin & Marta Soares & Nigel Rice & Eldon Spackman & Sebastian Hinde & Nancy Devlin & Peter C Smith & Mark Sculpher, 2013. "Methods for the estimation of the NICE cost effectiveness threshold," Working Papers 081cherp, Centre for Health Economics, University of York.

Articles

  1. Sebastian Hinde & Ros Wade & Stephen Palmer & Nerys Woolacott & Eldon Spackman, 2016. "Apremilast for the Treatment of Moderate to Severe Plaque Psoriasis: A Critique of the Evidence," PharmacoEconomics, Springer, vol. 34(6), pages 587-596, June.
  2. Sebastian Hinde & Eldon Spackman, 2015. "Bidirectional Citation Searching to Completion: An Exploration of Literature Searching Methods," PharmacoEconomics, Springer, vol. 33(1), pages 5-11, January.

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:
  1. Karl Claxton & Steve Martin & Marta Soares & Nigel Rice & Eldon Spackman & Sebastian Hinde & Nancy Devlin & Peter C Smith & Mark Sculpher, 2013. "Methods for the estimation of the NICE cost effectiveness threshold," Working Papers 081cherp, Centre for Health Economics, University of York.

    Mentioned in:

    1. Sofosbuvir: a fork in the road for NICE?
      by Chris Sampson in The Academic Health Economists' Blog on 2015-01-20 17:21:00
    2. Chris Sampson’s journal round-up for 22nd May 2017
      by Chris Sampson in The Academic Health Economists' Blog on 2017-05-22 16:00:45
    3. Rita Faria’s journal round-up for 18th June 2018
      by Rita Faria in The Academic Health Economists' Blog on 2018-06-18 11:00:47

Working papers

  1. Karl Claxton & Steve Martin & Marta Soares & Nigel Rice & Eldon Spackman & Sebastian Hinde & Nancy Devlin & Peter C Smith & Mark Sculpher, 2013. "Methods for the estimation of the NICE cost effectiveness threshold," Working Papers 081cherp, Centre for Health Economics, University of York.

    Cited by:

    1. Andrew J. Mirelman & Miqdad Asaria & Bryony Dawkins & Susan Griffin & Richard Cookson & Peter Berman, 2020. "Fairer Decisions, Better Health for All: Health Equity and Cost-Effectiveness Analysis," World Scientific Book Chapters, in: Paul Revill & Marc Suhrcke & Rodrigo Moreno-Serra & Mark Sculpher (ed.), Global Health Economics Shaping Health Policy in Low- and Middle-Income Countries, chapter 4, pages 99-132, World Scientific Publishing Co. Pte. Ltd..
    2. Eldon Spackman & Stewart Richmond & Mark Sculpher & Martin Bland & Stephen Brealey & Rhian Gabe & Ann Hopton & Ada Keding & Harriet Lansdown & Sara Perren & David Torgerson & Ian Watt & Hugh MacPherso, 2014. "Cost-Effectiveness Analysis of Acupuncture, Counselling and Usual Care in Treating Patients with Depression: The Results of the ACUDep Trial," PLOS ONE, Public Library of Science, vol. 9(11), pages 1-12, November.
    3. Adrian Towse;Paul Barnsley;Sarah Karlsberg-Schaffer;Jon Sussex, 2013. "Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold," Occasional Paper 000106, Office of Health Economics.
    4. Ulrikke J. V. Hernæs & Kjell A. Johansson & Trygve Ottersen & Ole F. Norheim, 2017. "Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss," PharmacoEconomics, Springer, vol. 35(9), pages 965-974, September.
    5. Pieter van Baal & David Meltzer & Werner Brouwer, 2016. "Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost‐Effectiveness Analysis," Health Economics, John Wiley & Sons, Ltd., vol. 25(2), pages 237-248, February.
    6. Paul Revill & Simon Walker & Valentina Cambiano & Andrew Phillips & Mark J Sculpher, 2018. "Reflecting the real value of health care resources in modelling and cost-effectiveness studies—The example of viral load informed differentiated care," PLOS ONE, Public Library of Science, vol. 13(1), pages 1-13, January.
    7. Hareth Al-Janabi & Job van Exel & Werner Brouwer & Joanna Coast, 2016. "A Framework for Including Family Health Spillovers in Economic Evaluation," Medical Decision Making, , vol. 36(2), pages 176-186, February.
    8. Linda Ryen & Mikael Svensson, 2015. "The Willingness to Pay for a Quality Adjusted Life Year: A Review of the Empirical Literature," Health Economics, John Wiley & Sons, Ltd., vol. 24(10), pages 1289-1301, October.
    9. Sebastian Hinde & Eldon Spackman, 2015. "Bidirectional Citation Searching to Completion: An Exploration of Literature Searching Methods," PharmacoEconomics, Springer, vol. 33(1), pages 5-11, January.
    10. Iftekhar Khan & Mandy Maredza & Melina Dritsaki & Dipesh Mistry & Ranjit Lall & Sarah E. Lamb & Keith Couper & Simon Gates & Gavin D. Perkins & Stavros Petrou, 2020. "Is Protocolised Weaning that Includes Early Extubation Onto Non-Invasive Ventilation More Cost Effective Than Protocolised Weaning Without Non-Invasive Ventilation? Findings from the Breathe Study," PharmacoEconomics - Open, Springer, vol. 4(4), pages 697-710, December.
    11. Ken Willis & Bob Crabtree & Liesl M. Osman & Kirsty Cathrine, 2016. "Green space and health benefits: a QALY and CEA of a mental health programme," Journal of Environmental Economics and Policy, Taylor & Francis Journals, vol. 5(2), pages 163-180, July.
    12. Simon Eckermann, 2015. "Kinky Thresholds Revisited: Opportunity Costs Differ in the NE and SW Quadrants," Applied Health Economics and Health Policy, Springer, vol. 13(1), pages 7-13, February.
    13. John Brazier & Aki Tsuchiya, 2015. "Improving Cross-Sector Comparisons: Going Beyond the Health-Related QALY," Applied Health Economics and Health Policy, Springer, vol. 13(6), pages 557-565, December.
    14. Ryen, Linda & Svensson, Mikael, 2014. "The Willingness to Pay for a QALY: a Review of the Empirical Literature," Karlstad University Working Papers in Economics 12, Karlstad University, Department of Economics.
    15. James F. O’Mahony & Mike Paulden & Chris McCabe, 2021. "NICE’s Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests," PharmacoEconomics, Springer, vol. 39(2), pages 139-146, February.
    16. Mike Paulden & Christopher McCabe, 2021. "Modifying NICE’s Approach to Equity Weighting," PharmacoEconomics, Springer, vol. 39(2), pages 147-160, February.
    17. Miqdad Asaria & Susan Griffin & Richard Cookson, 2016. "Distributional Cost-Effectiveness Analysis," Medical Decision Making, , vol. 36(1), pages 8-19, January.
    18. Donna Rowen & John Brazier & Clara Mukuria & Anju Keetharuth & Arne Risa Hole & Aki Tsuchiya & Sophie Whyte & Phil Shackley, 2016. "Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life," Medical Decision Making, , vol. 36(2), pages 210-222, February.
    19. B. Rodríguez-Sánchez & L. M. Peña-Longobardo & A. J. Sinclair, 2020. "Cost-effectiveness analysis of the Neuropad device as a screening tool for early diabetic peripheral neuropathy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 21(3), pages 335-349, April.
    20. Karlsberg Schaffer, Sarah & Sussex, Jon & Devlin, Nancy & Walker, Andrew, 2015. "Local health care expenditure plans and their opportunity costs," Health Policy, Elsevier, vol. 119(9), pages 1237-1244.
    21. Luigi Siciliani & James Gaughan & Nils Gutacker & Hugh Gravelle & Martin Chalkley, 2021. "Paying for health gains," Working Papers 183cherp, Centre for Health Economics, University of York.
    22. Beth Woods & Paul Revill & Mark Sculpher & Karl Claxton, 2015. "Country-level cost-effectiveness thresholds: initial estimates and the need for further research," Working Papers 109cherp, Centre for Health Economics, University of York.
    23. Mike Paulden & Christopher McCabe & Jonathan Karnon, 2014. "Achieving Allocative Efficiency in Healthcare: Nice in Theory, not so NICE in Practice?," PharmacoEconomics, Springer, vol. 32(4), pages 315-318, April.
    24. A. Newall & M. Jit & R. Hutubessy, 2014. "Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines," PharmacoEconomics, Springer, vol. 32(6), pages 525-531, June.
    25. Helen Weatherly & Rita Faria & Bernard Van den Berg & Mark Sculpher & Peter O’Neill & Kay Nolan & Julie Glanville & Jaana Isojarvi & Erin Baragula & Mary Edwards, 2017. "Scoping review on social care economic evaluation methods," Working Papers 150cherp, Centre for Health Economics, University of York.
    26. Charles E Phelps & Chris Cinatl, 2021. "Estimating optimal willingness to pay thresholds for cost‐effectiveness analysis: A generalized method," Health Economics, John Wiley & Sons, Ltd., vol. 30(7), pages 1697-1702, July.
    27. J. Jaime Caro & John E. Brazier & Jonathan Karnon & Peter Kolominsky-Rabas & Alistair J. McGuire & Erik Nord & Michael Schlander, 2019. "Determining Value in Health Technology Assessment: Stay the Course or Tack Away?," PharmacoEconomics, Springer, vol. 37(3), pages 293-299, March.
    28. Simon Eckermann & Brita Pekarsky, 2014. "Can the Real Opportunity Cost Stand Up: Displaced Services, the Straw Man Outside the Room," PharmacoEconomics, Springer, vol. 32(4), pages 319-325, April.
    29. Alan Haycox, 2016. "Why Cancer?," PharmacoEconomics, Springer, vol. 34(7), pages 625-627, July.
    30. Mark Sculpher & Stephen Palmer, 2020. "After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?," PharmacoEconomics, Springer, vol. 38(3), pages 247-257, March.
    31. Kinghorn, Philip & Afentou, Nafsika, 2021. "Eliciting a monetary threshold for a year of sufficient capability to inform resource allocation decisions in public health and social care," Social Science & Medicine, Elsevier, vol. 279(C).
    32. Mike Paulden & James O’Mahony & Anthony Culyer & Christopher McCabe, 2014. "Some Inconsistencies in NICE’s Consideration of Social Values," PharmacoEconomics, Springer, vol. 32(11), pages 1043-1053, November.
    33. J. Raftery, 2014. "NICE’s Cost-Effectiveness Range: Should it be Lowered?," PharmacoEconomics, Springer, vol. 32(7), pages 613-615, July.
    34. Stephen Martin & James Lomas & Karl Claxton & Francesco Longo, 2021. "How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13," Applied Health Economics and Health Policy, Springer, vol. 19(6), pages 885-903, November.
    35. Paul Revill & Simon Walker & Jason Madan & Andrea Ciaranello & Takondwa Mwase & Diana M Gibb & Karl Claxton & Mark J Sculpher, 2014. "Using cost-effectiveness thresholds to determine value for money in low- and middle-income country healthcare systems: Are current international norms fit for purpose?," Working Papers 098cherp, Centre for Health Economics, University of York.
    36. Torbjørn Wisløff & Gunhild Hagen & Vida Hamidi & Espen Movik & Marianne Klemp & Jan Olsen, 2014. "Estimating QALY Gains in Applied Studies: A Review of Cost-Utility Analyses Published in 2010," PharmacoEconomics, Springer, vol. 32(4), pages 367-375, April.
    37. Alec Morton & Amanda I. Adler & David Bell & Andrew Briggs & Werner Brouwer & Karl Claxton & Neil Craig & Alastair Fischer & Peter McGregor & Pieter van Baal, 2016. "Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal," Health Economics, John Wiley & Sons, Ltd., vol. 25(8), pages 933-938, August.
    38. Jessica Ochalek & Haiyin Wang & Yuanyuan Gu & James Lomas & Henry Cutler & Chunlin Jin, 2020. "Informing a Cost-Effectiveness Threshold for Health Technology Assessment in China: A Marginal Productivity Approach," PharmacoEconomics, Springer, vol. 38(12), pages 1319-1331, December.
    39. Wildman, John & McMeekin, Peter & Grieve, Eleanor & Briggs, Andrew, 2016. "Economic evaluation of integrated new technologies for health and social care: Suggestions for policy makers, users and evaluators," Social Science & Medicine, Elsevier, vol. 169(C), pages 141-148.
    40. Doug Coyle & Matthew C. Cheung & Gerald A. Evans, 2014. "Opportunity Cost of Funding Drugs for Rare Diseases," Medical Decision Making, , vol. 34(8), pages 1016-1029, November.
    41. Asaria, Miqdad & Griffin, Susan & Cookson, Richard, 2016. "Distributional cost-effectiveness analysis: a tutorial," LSE Research Online Documents on Economics 101271, London School of Economics and Political Science, LSE Library.
    42. Emma Cowles & Grace Marsden & Amanda Cole & Nancy Devlin, 2017. "A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?," Applied Health Economics and Health Policy, Springer, vol. 15(4), pages 469-477, August.
    43. Mark Sculpher, 2013. "Methods Development for Health Technology Assessment," Medical Decision Making, , vol. 33(3), pages 313-315, April.
    44. Peter J. Neumann & David D. Kim & Thomas A. Trikalinos & Mark J. Sculpher & Joshua A. Salomon & Lisa A. Prosser & Douglas K. Owens & David O. Meltzer & Karen M. Kuntz & Murray Krahn & David Feeny & An, 2018. "Future Directions for Cost-effectiveness Analyses in Health and Medicine," Medical Decision Making, , vol. 38(7), pages 767-777, October.
    45. Bevan, Gwyn & Brown, Lawrence D., 2014. "The political economy of rationing health care in England and the US: the ‘accidental logics’ of political settlements," LSE Research Online Documents on Economics 57129, London School of Economics and Political Science, LSE Library.
    46. Mike Paulden & Tania Stafinski & Devidas Menon & Christopher McCabe, 2015. "Value-Based Reimbursement Decisions for Orphan Drugs: A Scoping Review and Decision Framework," PharmacoEconomics, Springer, vol. 33(3), pages 255-269, March.
    47. Drew Carter & Arlene Vogan & Hossein Haji Ali Afzali, 2016. "Governments Need Better Guidance to Maximise Value for Money: The Case of Australia’s Pharmaceutical Benefits Advisory Committee," Applied Health Economics and Health Policy, Springer, vol. 14(4), pages 401-407, August.
    48. Pieter van Baal & Meg Perry‐Duxbury & Pieter Bakx & Matthijs Versteegh & Eddy van Doorslaer & Werner Brouwer, 2019. "A cost‐effectiveness threshold based on the marginal returns of cardiovascular hospital spending," Health Economics, John Wiley & Sons, Ltd., vol. 28(1), pages 87-100, January.
    49. Brick, Aoife & Gorecki, Paul K. & Nolan, Anne, 2013. "Ireland: Pharmaceutical Prices, Prescribing Practices and Usage of Generics in a Comparative Context," Research Series, Economic and Social Research Institute (ESRI), number RS32.

Articles

  1. Sebastian Hinde & Eldon Spackman, 2015. "Bidirectional Citation Searching to Completion: An Exploration of Literature Searching Methods," PharmacoEconomics, Springer, vol. 33(1), pages 5-11, January.

    Cited by:

    1. Henriette Busk & Ulrik Sidenius & Line Planck Kongstad & Sus Sola Corazon & Christina Bjørk Petersen & Dorthe Varning Poulsen & Patrik Karlsson Nyed & Ulrika Karlsson Stigsdotter, 2022. "Economic Evaluation of Nature-Based Therapy Interventions—A Scoping Review," Challenges, MDPI, vol. 13(1), pages 1-19, May.
    2. Dan Rigby & Caroline Vass & Katherine Payne, 2020. "Opening the ‘Black Box’: An Overview of Methods to Investigate the Decision-Making Process in Choice-Based Surveys," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 13(1), pages 31-41, February.
    3. Christopher W. Belter, 2017. "A relevance ranking method for citation-based search results," Scientometrics, Springer;Akadémiai Kiadó, vol. 112(2), pages 731-746, August.
    4. Sebastian Hinde & Laura Bojke & Peter Coventry, 2021. "The Cost Effectiveness of Ecotherapy as a Healthcare Intervention, Separating the Wood from the Trees," IJERPH, MDPI, vol. 18(21), pages 1-13, November.
    5. Oliver Werth & Davinia Rodríguez Cardona & Albert Torno & Michael H. Breitner & Jan Muntermann, 2023. "What determines FinTech success?—A taxonomy-based analysis of FinTech success factors," Electronic Markets, Springer;IIM University of St. Gallen, vol. 33(1), pages 1-22, December.
    6. Davy, Elder & Hansen, Ulrich E., 2023. "A firm-level perspective on windows of opportunity," Technology in Society, Elsevier, vol. 75(C).

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Co-authorship network on CollEc

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Sebastian Hinde should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.

IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.